Inhalable siRNA: Potential as a therapeutic agent in the lungs

Molecular Pharmaceutics

Volumn 5, Issue 4, 2008, Pages 559-566

  Durcan, Niamh ^a   Murphy, Charlotte ^a   Cryan, Sally Ann ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Inhalation; Lungs; Respiratory disease; SiRNA

Indexed keywords

BORTEZOMIB; CAVEOLIN 1; CHITOSAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GREEN FLUORESCENT PROTEIN; HEME OXYGENASE 1; INTERLEUKIN 4; INTERLEUKIN 8; LIPID; LIPOFECTAMINE; NANOPARTICLE; POLYETHYLENEIMINE; POLYMER; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1C; RAS PROTEIN; RETINOIC ACID RECEPTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; VALOSIN CONTAINING PROTEIN;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SPECIFICITY; GENE CONTROL; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; LUNG CANCER; LUNG DISEASE; LUNG INFECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM;

ADMINISTRATION, INHALATION; ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; LUNG DISEASES; RNA, SMALL INTERFERING; TITRIMETRY;

EID: 51049084639     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp070048k     Document Type: Conference Paper

References (62)

1. Novina, C. D.; Sharp, P. A. The RNAi revolution. Nature 2004, 430 (6996), 161-4.
2. Rana, T. M. Illuminating the silence: understanding the structure and function of small RNAs. Nat. Rev. Mol. Cell Biol. 2007, 8 (1), 23-36.
3. Osborne, S. E.; Matsumura, I.; Ellington, A. D. Aptamers as therapeutic and diagnostic reagents: problems and prospects. Curr. Opin. Chem. Biol. 1997, 1 (1), 5-9.
4. Van Oekelen, D.; Luyten, W. H.; Leysen, J. E. Ten years of antisense inhibition of brain G-protein-coupled receptor function. Brain Res. Brain Res. Rev. 2003, 42 (2), 123-42.
5. Stein, C. A. The experimental use of antisense oligonucleotides: a guide for the perplexed. J. Clin. Invest. 2001, 108 (5), 641-4.
6. Gary, D. J.; Puri, N.; Won, Y. Y. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J. Controlled Release 2007, 121(1-2), 64-73.
7. Sioud, M. RNA interference and innate immunity. Adv. Drug Delivery Rev. 2007, 59 (2-3), 153-63.
8. Amarzguioui, M.; Prydz, H. An algorithm for selection of functional siRNA sequences. Biochem. Biophys. Res. Commun. 2004, 316 (4), 1050-8.
9. Huesken, D.; Lange, J.; Mickanin, C.; Weiler, J.; Asselbergs, F.; Warner, J.; Meloon, B.; Engel, S.; Rosenberg, A.; Cohen, D.; Labow, M.; Reinhardt, M.; Natt, F.; Hall, J. Design of a genomewide siRNA library using an artificial neural network. Nat. Biotechnol. 2005, 23 (8), 995-1001.
10. Khvorova, A.; Reynolds, A.; Jayasena, S. D. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003, 115 (2), 209-16.
11. Reynolds, A.; Leake, D.; Boese, Q.; Scaringe, S.; Marshall, W. S.; Khvorova, A. Rational siRNA design for RNA interference. Nat. Biotechnol. 2004, 22 (3), 326-30.
12. Ui-Tei, K.; Naito, Y.; Takahashi, F.; Haraguchi, T.; Ohki-Hamazaki, H.; Juni, A.; Ueda, R.; Saigo, K. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 2004, 32 (3), 936-48.
13. Buchholz, F.; Kittler, R.; Slabicki, M.; Theis, M. Enzymatically prepared RNAi libraries. Nat. Methods 2006, 3 (9), 696-700.
14. Hall, A. H.; Wan, J.; Shaughnessy, E. E.; Ramsay Shaw, B.; Alexander, K. A. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res. 2004, 32 (20), 5991-6000.
15. Amarzguioui, M.; Holen, T.; Babaie, E.; Prydz, H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 2003, 31 (2), 589-95.
16. Braasch, D. A.; Jensen, S.; Liu, Y.; Kaur, K.; Arar, K.; White, M. A.; Corey, D. R. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 2003, 42 (26), 7967-75.
17. Chiu, Y. L.; Rana, T. M. siRNA function in RNAi: a chemical modification analysis. RNA 2003, 9 (9), 1034-48.
18. Harborth, J.; Elbashir, S. M.; Vandenburgh, K.; Manninga, H.; Scaringe, S. A.; Weber, K.; Tuschl, T. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 2003, 13 (2), 83-105.
19. Sioud, M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2′-hydroxyl uridines in immune responses. Eur. J. Immunol. 2006, 36 (5), 1222-30.
20. Sioud, M.; Furset, G.; Cekaite, L. Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAs. Biochem. Biophys. Res. Commun. 2007, 361 (1), 122-6.
21. Martinez, L. A.; Naguibneva, I.; Lehrmann, H.; Vervisch, A.; Tchenio, T.; Lozano, G.; Harel-Bellan, A. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (23), 14849-54.
22. Zentilin, L.; Giacca, M. In vivo transfer and expression of genes coding for short interfering RNAs. Curr. Pharm Biotechnol. 2004, 5 (4), 341-7.
23. Shen, C.; Buck, A. K.; Liu, X.; Winkler, M.; Reske, S. N. Gene silencing by adenovirus-delivered siRNA. FEBS Lett. 2003, 539 (1-3), 111-4.
24. Narvaiza, I.; Aparicio, O.; Vera, M.; Razquin, N.; Bortolanza, S.; Prieto, J.; Fortes, P. Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing. J. Virol. 2006, 80 (24), 12236-47.
25. Teichler Zallen, D. US gene therapy in crisis. Trends Genet. 2000, 16 (6), 272-5.
26. Musiyenko, A.; Bitko, V.; Batik, S. RNAi-dependent and -independent antiviral phenotypes of chromosomally integrated shRNA clones: role of VASP in respiratory syncytial virus growth. J. Mol. Med. 2007, 85 (7), 745-52.
27. Buttgereit, P.; Weineck, S.; Ropke, G.; Marten, A.; Brand, K.; Heinicke, T.; Caselmann, W. H.; Huhn, D.; Schmidt-Wolf, I. G. Efficient gene transfer into lymphoma cells using adenoviral vectors combined with lipofection. Cancer Gene Ther. 2000, 7 (8), 1145-55.
28. Demeneix, B.; Behr, J. P. Polyethylenimine (PEI). Adv. Genet. 2005, 53, 217-30.
29. Feigner, P. L.; Ringold, G. M. Cationic liposome-mediated transfection. Nature 1989, 337 (6205), 387-8.
30. Goren, D.; Horowitz, A. T.; Tzemach, D.; Tarshish, M.; Zalipsky, S.; Gabizon, A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 2000, 6 (5), 1949-57.
31. Lv, H.; Zhang, S.; Wang, B.; Cui, S.; Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Controlled Release 2006, 114 (1), 100-9.
32. Semple, S. C.; Klimuk, S. K.; Harasym, T. O.; Dos Santos, N.; Ansell, S. M.; Wong, K. F.; Maurer, N.; Stark, H.; Cullis, P. R.; Hope, M. J.; Scherrer, P. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta 2001, 1510 (1-2), 152-66.
33. Thomas, M.; Lu, J. J.; Ge, Q.; Zhang, C.; Chen, J.; Klibanov, A. M. Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (16), 5679-84.
34. Ge, Q.; Filip, L.; Bai, A.; Nguyen, T.; Eisen, H. N.; Chen, J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (23), 8676-81.
35. Kleemann, E.; Neu, M.; Jekel, N.; Fink, L.; Schmehl, T.; Gessler, T.; Seeger, W.; Kissel, T. Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J. Controlled Release 2005, 109 (1-3), 299-316.
36. Howard, K. A.; Rahbek, U. L.; Liu, X.; Damgaard, C. K.; Glud, S. Z.; Andersen, M. O.; Hovgaard, M. B.; Schmitz, A.; Nyengaard, J. R.; Besenbacher, F.; Kjems, J. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 2006, 14 (4), 476-84.
37. Bitko, V.; Musiyenko, A.; Shulyayeva, O.; Batik, S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 2005, 11 (1), 50-5.
38. Grossman, J. The evolution of inhaler technology. J Asthma 1994, 31 (1), 55-64.
39. Gautam, A.; Waldrep, J. C.; Densmore, C. L. Aerosol gene therapy. Mol. Biotechnol. 2003, 23 (1), 51-60.
40. Stribling, R.; Brunette, E.; Liggitt, D.; Gaensler, K.; Debs, R. Aerosol gene delivery in vivo. Proc. Natl. Acad. Sci. U.S.A. 1992, 89 (23), 11277-81.
41. Thomas, M.; Lu, J. J.; Chen, J.; Klibanov, A. M. Non-viral siRNA delivery to the lung. Adv. Drug Delivery Rev. 2007, 59 (2-3), 124-33.
42. Tompkins, S. M.; Lo, C. Y.; Tumpey, T. M.; Epstein, S. L. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (23), 8682-6.
43. Massaro, D.; Massaro, G. D.; Clerch, L. B. Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. Am. J. Physiol:. Lung Cell. Mol. Physiol. 2004, 287 (5), L 1066-70.
44. Li, B. J.; Tang, Q.; Cheng, D.; Qin, C.; Xie, F. Y.; Wei, Q.; Xu, J.; Liu, Y.; Zheng, B. J.; Woodle, M. C.; Zhong, N.; Lu, P. Y. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat. Med. 2005, 11 (9), 944-51.
45. Hickey, A. J.; Garcia-Contreras, L. Immunological and toxicological implications of short-term studies in animals of pharmaceutical aerosol delivery to the lungs: relevance to humans. Crit. Rev. Ther. Drug Carrier Syst. 2001, 18 (4), 387-431.
46. Beck, S. E.; Laube, B. L.; Barberena, C. I.; Fischer, A. C.; Adams, R. J.; Chesnut, K.; Flotte, T. R.; Guggino, W. B. Deposition and expression of aerosolized rAAV vectors in the lungs of Rhesus macaques. Mol. Ther. 2002, 6 (4), 546-54.
47. Ren, S. H.; Zhang, W.; Qu, P.; Liu, Y.; Wang, J. W.; Zhang, L. [Effect of RNAi-mediated gene silencing of C-erbB-2 on proliferation of lung adenocarcinoma cell line calu-3]. Aizheng 2005, 24 (10), 1173-8.
48. Ren, S. H.; Wang, J. W.; Zhang, L. [Effects of Her-2/neu siRNA-mediated gene silencing on cell cycle and apoptosis of lung adenocarcinoma cells]. Zhonghua Yi Xue Za Zhi 2005, 85 (22), 1530-4.
49. Zhang, Z.; Jiang, G.; Yang, F.; Wang, J. Knockdown of Mutant K-ras Expression by Adenovirus-Mediated siRNA Inhibits the In Vitro and in Vivo Growth of Lung Cancer Cells. Cancer Biol. Ther. 2006, 5 (11), 1481-6.
50. Han, S. W.; Roman, J. Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: prooncogenic effects mediated by PI3-kinase and NF-kappa B. Oncogene 2006, 25 (31), 4341-9.
51. Vij, N.; Fang, S.; Zeitlin, P. L. Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J. Biol. Chem. 2006, 281 (25), 17369-78.
52. Bradding, P.; Walls, A. F.; Holgate, S. T. The role of the mast cell in the pathophysioiogy of asthma. J. Allergy Clin. Immunol. 2006, 117 (6), 1277-84.
53. Bumcrot, D.; Manoharan, M.; Koteliansky, V.; Sah, D. W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2006, 2 (12), 711-9.
54. Amaar, Y. G.; Minera, M. G.; Hatran, L. K.; Strong, D. D.; Mohan, S.; Reeves, M. E. Ras association domain family IC protein stimulates human lung cancer cell proliferation. Am. J. Physiol.: Lung Cell. Mol. Physiol. 2006, 291 (6), L1185-90.
55. Miyawaki-Shimizu, K.; Predescu, D.; Shimizu, J.; Broman, M.; Predescu, S.; Malik, A. B. siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathway. Am. J. Physiol.: Lung Cell. Mol. Physiol. 2006, 290 (2), L405-13.
56. Yin, J. Q.; Gao, J.; Shao, R.; Tian, W. N., Wang, J.; Wan, Y. siRNA agents inhibit oncogene expression and attenuate human tumor cell growth. J. Exp. Ther. Oncol. 2003, 3 (4), 194-204.
57. Uematsu, K.; He, B.; You, L.; Xu, Z.; McCormick, F.; Jablons, D. M. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 2003, 22 (46), 7218-21.
58. Aggarwal, S.; Kim, S. W.; Cheon, K.; Tabassam, F. H.; Yoon, J. H.; Koo, J. S. Nonclassical action of retinoic acid on the activation of the cAMP response element-binding protein in normal human bronchial epithelial cells. Mol. Biol. Cell 2006, 17 (2), 566-75.
59. Shieh, Y. S.; Lai, C. Y.; Kao, Y. R.; Shiah, S. G.; Chu, Y. W.; Lee, H. S.; Wu, C. W. Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 2005, 7 (12), 1058-64.
60. Zhang, X.; Shan, P.; Jiang, D.; Noble, P. W.; Abraham, N. G.; Kappas, A.; Lee, P. J. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J. Biol. Chem. 2004, 279 (11), 10677-84.
61. Kong, X.; Zhang, W.; Lockey, R. F.; Auais, A.; Piedimonte, G.; Mohapatra, S. S. Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene. Genet. Vaccines Ther. 2007, 5 4.
62. Aigner, A. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J. Biotechnol. 2006, 124(1), 12-25.